HAPLN3 and pachyonychia congenita: Haldrup et al. showed that CCDC181 (C1orf114) and HAPLN3 can be used as novel biomarkers for the hypermethylation of prostate cancer (PC), proving to be a novel diagnostic and/or prognostic promoter.